Abstract
Biomarkers are defined as anatomic, physiologic, biochemical, molecular, or genetic parameters associated with the presence, absence, or severity of a disease process. As such, biomarkers may be useful as prognostic and diagnostic tests. Establishing the utility of a given biomarker as a prognostic or diagnostic test requires the conduct of carefully designed cohort studies in which the biomarker and the outcome of interest are measured independently. The design and analysis of such studies is discussed. Surrogate outcomes in clinical trials consist of events or biomarkers intended to reflect important clinical outcomes. Surrogate outcomes may offer advantages in providing statistically robust estimates of treatment effects with smaller sample sizes. However, to be useful, surrogate outcomes have to be validated to ensure that the effect of therapy on them truly reflects the effect of therapy on the important clinical outcomes of interest.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT (2006) Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105:485–491
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therap 69:89–95
Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631–2639
Sackett D, Haynes R, Guyatt G, Tugwell P (1991) The interpretation of diagnostic data. In: Sackett DL et al (eds) Clinical epidemiology: a basic science for clinical medicine, 2nd edn. Little, Brown and Company, Toronto, ON
Kleinbaum DG (1996) Survival analysis: a self-learning text. Springer, New York, NY
Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall/CRC, Boca Raton, FL
Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109–2123
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172, discussion 207–212
Pencina MJ, D’Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11–21
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology 99:1373–1379
Hanley J, McNeil B (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36
Mulherin SA, Miller WC (2002) Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med 137:598–602
Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304–1316
LaRosa JC, Grundy SM, Waters D, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435
Baker AG, Kramer BS (2003) A perfect correlate does not a surrogate make. BMC Med Res Methodol 3:16–21
Prentice RL (1989) Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med 8:431–440
Gail MH, Pfeiffer R, Houwelingen HC, Carroll RJ (2001) On meta-analytic assessment of surrogate outcomes. Biostatistics 3:231–246
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Rigatto, C., Barrett, B.J. (2015). Randomized Controlled Trials 4: Biomarkers and Surrogate Outcomes. In: Parfrey, P., Barrett, B. (eds) Clinical Epidemiology. Methods in Molecular Biology, vol 1281. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2428-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2428-8_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2427-1
Online ISBN: 978-1-4939-2428-8
eBook Packages: Springer Protocols